


CONCORD DRUGS LIMITED

(A PHARMACEUTICAL FORMULATIONS UNIT)

CORPORATE OFFICE : # 3-11-1/1, L.B. Nagar, Hyderabad - 500 074. A.P. India.

Tel : 091-40-24037763, 24036379

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st December, 2014							
Statement of Standalone (Un-audited) / Audited Results for the Quarter ended 31/12/2014							
Sl. No.	Particulars	Standalone					Year Ended 31.03.2014 (Audited)
		Three months Ended 31.12.2014 (Un-Audited)	Three months ended 30.09.2014 (Un-Audited)	Three months Ended 31.12.2013 (Un-Audited)	Months Ended 31.12.2014 (Un-Audited)	Months ended Ended 31.12.2013 (Un-Audited)	
		Rs in Lacs					
1	Income from Operations :						
	(a) Net Sales / Income from Operations (Net of Excise Duty)	1,008.25	872.28	881.25	2,930.76	2,456.00	3,395.21
	(b) Other Directs Income	2.91	2.89	3.70	10.14	7.89	12.25
	Total Income From operations (net)	1,011.16	875.15	884.95	2,940.90	2,463.89	3,407.46
2	Expenses						
	(a) Operating Expenses	36.84	37.20	33.26	112.45	83.72	121.84
	(b) Purchases of stock in trade	780.05	756.36	715.95	2,278.97	2,003.38	2,760.83
	(c) Changes in inventories of finished goods, Work-in-progress and stock-in-trade	(3.45)	(3.25)	(2.50)	(9.15)	(5.82)	(9.70)
	(d) Employee benefits expense	13.95	13.21	13.05	40.39	33.54	47.40
	(e) Depreciation and amortisation expense	87.04	87.04	30.25	201.12	81.75	114.25
	(f) Power And Fuel	13.25	13.05	12.24	38.48	37.89	50.00
	(g) Freight and Forwarding Expenses	5.42	5.32	4.78	14.95	11.88	16.79
	(h) Other Expenses	15.29	13.32	20.95	40.96	62.56	85.30
	Total Expenses (a+b+c+d+e+f+g+h)	930.66	902.31	826.98	2,716.16	2,308.00	3,166.56
	Profit/(Loss) from operations before other income and finance costs (1-2)	80.48	72.84	57.97	224.74	155.88	220.90
3	Other Income						
	Profit/(Loss) from ordinary activities before finance cost (3+4-1)	80.48	72.84	57.97	224.74	155.88	220.90
4	Finance cost	84.15	57.84	47.25	179.00	125.13	170.05
5	Profit/(Loss) from ordinary activities before Tax (5+4-1)	-3.67	15.00	10.72	45.74	30.75	50.85
6	Tax expense						
	(a) Current Tax	3.54	2.78	2.00	10.33	8.00	8.97
	(b) Deferred Tax	-	-	-	-	-	-
	Total (a+b)	3.54	2.78	2.00	10.33	8.00	8.97
7	Net Profit/(Loss) for the period (7+5-6)	(2.79)	12.22	8.72	35.41	22.75	41.88
8	Minority Interest						
9	Net Profit/(Loss) after Taxes and minority interest (8+7-8)	(2.79)	12.22	8.72	35.41	22.75	41.88
10	Paid up Equity Share Capital (Face value of Rs.10/- per share) less Reserve excluding Reserve as per balance sheet at year end	724.38	724.38	724.38	724.38	724.38	724.38
11	Earnings Per Share (of Rs.10/- each) (not annualised)						
	(a) Basic	0.18	0.17	0.12	0.48	0.34	0.47
	(b) Diluted	0.18	0.17	0.12	0.48	0.34	0.47
Part B							
Select Information for the Quarter Ended 31/12/2014							
Sl. No.	Particulars	Standalone					Year Ended 31.03.2014 (Audited)
		Three months Ended 31.12.2014 (Un-Audited)	Three months ended 30.09.2014 (Un-Audited)	Three months Ended 31.12.2013 (Un-Audited)	Months Ended 31.12.2014 (Un-Audited)	Months ended Ended 31.12.2013 (Un-Audited)	
		Rs in Lacs					
1	Public Shareholding						
	- Number of shares (000's)	4403250	4403250	4403250	4403250	4403250	4403250
	- Percentage of Shareholding	80.79%	80.79%	80.79%	80.79%	80.79%	80.79%
2	Promoter and Promoter group Shareholding (Excluding GDRs)						
	(a) Pledged/Encumbered						
	- Number of Shares (000's)	-	-	-	-	-	-
	- Percentage of shares (As a % of total shareholding of Promoter and promoter group)	-	-	-	-	-	-
	- Percentage of shares (As a % of total share Capital of the Company)	-	-	-	-	-	-
	(b) Non-Encumbered						
	- Number of Shares (000's)	2840500	2840500	2840500	2840500	2840500	2840500
	- Percentage of shares (As a % of total shareholding of Promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (As a % of total share Capital of the Company)	39.21%	39.21%	39.21%	39.21%	39.21%	39.21%
3	Particulars	The Months ended 31/12/2014					
	INVESTOR COMPLAINTS						
	Pending at the beginning of the quarter	Nil	Nil	Nil	Nil	Nil	Nil
	Received during the quarter	Nil	Nil	Nil	Nil	Nil	Nil
	Disposed of during the quarter	Nil	Nil	Nil	Nil	Nil	Nil
	Remaining un-resolved at the end of the quarter	Nil	Nil	Nil	Nil	Nil	Nil
Required Subsequent							
1	The above results were reviewed by the Audit Committee of Directors and taken on record by the Board of Directors at their meeting held on 14.02.2015						
2	The Accounting Standard 17 relating to Segment was reporting is not applicable as the company operates in only one segment						
3	There were no complaints from investors outstanding at the beginning of the quarter ended 31st December 2014 and the Company has not received any complaints during the quarter ended 31st December 2014						
4	Previous period / year figures have been regrouped wherever necessary						
Station: HYDERABAD Date: 14.02.2015		 For Concord Drugs Limited Managing Director					